US 11,859,217 B2
Terminal deoxynucleotidyl transferase variants and uses thereof
Elise Champion, Paris (FR); Jéröme Loc'h, Le Kremlin-Bicétre (FR); Mikhael Soskine, Franconville (FR); and Elodie Sune, Le Kremlin-Bicétre (FR)
Assigned to DNA Script, Le Kremlin Bicêtre (FR)
Appl. No. 17/293,017
Filed by DNA Script, Le Kremlin-Bicétre (FR)
PCT Filed Nov. 13, 2019, PCT No. PCT/EP2019/081099
§ 371(c)(1), (2) Date May 11, 2021,
PCT Pub. No. WO2020/099451, PCT Pub. Date May 22, 2020.
Claims priority of application No. 18206298 (EP), filed on Nov. 14, 2018; application No. 19305677 (EP), filed on May 28, 2019; and application No. 19195662 (EP), filed on Sep. 5, 2019.
Prior Publication US 2022/0002687 A1, Jan. 6, 2022
Int. Cl. C12N 9/12 (2006.01)
CPC C12N 9/1264 (2013.01) [C12Y 207/07031 (2013.01)] 10 Claims
 
1. A terminal deoxynucleotidyl transferase (TdT) variant comprising an amino acid sequence at least ninety percent identical to the amino acid sequence of SEQ ID NO: 3 with a substitution at positions Q326 and K265, wherein the TdT variant (i) is capable of synthesizing a nucleic acid fragment without a template and (ii) is capable of incorporating a 3′-O-modified nucleotide onto a nucleic acid fragment.